Clincosm LogoSign in Get a demo

Hepatocellular Carcinoma

Showing NaN - NaN of 148
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Shanghai (AK104, )

Not yet recruiting
  • Hepatocellular Carcinoma
  • AK104
  • placebo
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 4, 2022

Hepatocellular Carcinoma Trial in Shanghai (lenvatinib, TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Huashan hospital
Jul 29, 2022

Hepatocellular Carcinoma Trial in Worldwide (Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Birmingham, Alabama
  • +132 more
Jul 20, 2022

Solid Tumors, NSCLC, Renal Cell Carcinoma Trial in China (Lenvatinib + Envafolimab, Sunitinib)

Recruiting
  • Solid Tumors
  • +3 more
  • Benbu, Anhui, China
  • +22 more
Jun 28, 2022

Early Diagnosis of Digestive System Cancers

Recruiting
  • Esophageal Cancer
  • +3 more
    • Shanghai, Shanghai, China
    • +3 more
    Jun 19, 2022

    Hepatocellular Carcinoma Trial in Worldwide (Tremelimumab, Durvalumab, Bevacizumab)

    Active, not recruiting
    Has Results
    • Hepatocellular Carcinoma
    • Tremelimumab
    • +2 more
    • Phoenix, Arizona
    • +43 more
    Jun 22, 2022

    Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in China (Observation)

    Recruiting
    • Primary Liver Cancer
    • +3 more
    • Observation
    • Beijing, Beijing, China
    • +4 more
    Jun 14, 2022

    Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    May 30, 2022

    Hepatocellular Carcinoma Trial in Shanghai (Multifocal Stereotactic Radiotherapy, Atezolizumab Injection [Tecentriq],

    Recruiting
    • Hepatocellular Carcinoma
    • Multifocal Stereotactic Radiotherapy
    • +2 more
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    May 27, 2022

    Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

    Recruiting
    • Hepatocellular Carcinoma
    • SCG101
    • PD1/PD-L1 checkpoint inhibitor
    • Beijing, China
    • +3 more
    May 7, 2022

    NSCLC, Small Cell Lung Cancer, Pancreas Cancer Trial in Shanghai (Infusion of iNKT cells and CD8+T cells)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • +5 more
    • Infusion of iNKT cells and CD8+T cells
    • Shanghai, Shanghai, China
      Shanghai Public Health Clinical Center
    May 6, 2022

    Hepatocellular Carcinoma Trial in China (microwave ablation)

    Recruiting
    • Hepatocellular Carcinoma
    • microwave ablation
    • Beijing, Beijing, China
    • +12 more
    May 4, 2022

    NSCLC, Gastric Cancer, Hepatocellular Carcinoma Trial in Beijing, Shanghai (natural killer T cell)

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • natural killer T cell
    • Beijing, China
    • +1 more
    Apr 26, 2022

    Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma Trial in Shanghai (radiation, combination product, drug)

    Not yet recruiting
    • Liver Cancer
    • +4 more
    • intensity-modulated radiotherapy
    • +5 more
    • Shanghai, China
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
    Apr 20, 2022

    A Single Center Real-world Study of Donafenib in Treatment of

    Recruiting
    • Donafenib
    • Hepatocellular Carcinoma
      • Shanghai, Shanghai, China
        Zhongshan Hospital, Fudan University,
      Mar 17, 2022

      Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b

      Recruiting
      • Hepatocellular Carcinoma
      • Shanghai, China
        Zhongshan Hospital, Fudan University
      Mar 28, 2022

      Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2))

      Recruiting
      • Hepatocellular Carcinoma
      • Los Angeles, California
      • +173 more
      Mar 25, 2022

      Donafenib Combined With TACE-based Treatment in Unresectable HCC

      Recruiting
      • Hepatocellular Carcinoma
      • Donafenib
      • Donafenib combined with TACE
      • Shanghai, China
        Fudan University
      Mar 21, 2022

      Hepatocellular Carcinoma Trial in China (CAR-GPC3 T Cells)

      Completed
      • Hepatocellular Carcinoma
      • CAR-GPC3 T Cells
      • Guangzhou, Guangdong, China
      • +5 more
      Feb 8, 2022

      Hepatocellular Carcinoma Trial in Worldwide (Ramucirumab, Placebo)

      Completed
      Has Results
      • Hepatocellular Carcinoma
      • Daly City, California
      • +130 more
      Jan 5, 2022

      Hepatocellular Carcinoma Trial in Shanghai (HLX10 3mg/kg, HLX04 5mg/kg, HLX04 10mg/kg)

      Active, not recruiting
      • Hepatocellular Carcinoma
      • HLX10 3mg/kg
      • +2 more
      • Shanghai, China
        Ethics committee of zhongshan hospital affiliated to fudan unive
      Dec 30, 2021

      Hepatocellular Carcinoma Trial in Shanghai (TORIPALIMAB INJECTION(JS001 ))

      Active, not recruiting
      • Hepatocellular Carcinoma
      • TORIPALIMAB INJECTION(JS001 )
      • Shanghai, Shanghai, China
        Zhongshan Hospital,Fudan University
      Nov 23, 2021

      Hepatocellular Carcinoma Trial in Shanghai (carbon-ion radiotherapy for tumor away from GI, carbon-ion radiotherapy for tumor

      Recruiting
      • Hepatocellular Carcinoma
      • carbon-ion radiotherapy for tumor away from GI
      • carbon-ion radiotherapy for tumor adjacent to GI
      • Shanghai, Shanghai, China
        Shanghai Proton and Heavy Ion Center
      Nov 21, 2021

      Hepatocellular Carcinoma Trial in Shanghai (IPM001)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • IPM001
      • Shanghai, Shanghai, China
        Huashan hospital Fudan university
      Oct 23, 2021

      Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial in China (Lenvatinib,

      Recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Hefei, Anhui, China
      • +9 more
      Oct 21, 2021